<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Cervomed Inc. — News on 6ix</title>
<link>https://6ix.com/company/cervomed-inc</link>
<description>Latest news and press releases for Cervomed Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/cervomed-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835599a78dffbe2df0eb1d1.webp</url>
<title>Cervomed Inc.</title>
<link>https://6ix.com/company/cervomed-inc</link>
</image>
<item>
<title>CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies</title>
<link>https://6ix.com/company/cervomed-inc/news/cervomed-announces-new-data-at-the-2026-aan-annual-meeting-that-demonstrated-neflamapimod-increased-basal-forebrain-volume-and-functional-connectivity-in-dementia-with-lewy-bodies-11</link>
<guid isPermaLink="true">https://6ix.com/company/cervomed-inc/news/cervomed-announces-new-data-at-the-2026-aan-annual-meeting-that-demonstrated-neflamapimod-increased-basal-forebrain-volume-and-functional-connectivity-in-dementia-with-lewy-bodies-11</guid>
<pubDate>Wed, 22 Apr 2026 04:00:00 GMT</pubDate>
<description>Results consistent with pre-clinical studies demonstrating that, in the early stages of the neurodegenerative process, disease progression in the basal</description>
</item>
<item>
<title>CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting</title>
<link>https://6ix.com/company/cervomed-inc/news/cervomed-to-provide-neflamapimod-clinical-program-update-and-participate-in-a-panel-on-biomarkers-at-2026-lewy-body-dementia-association-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/cervomed-inc/news/cervomed-to-provide-neflamapimod-clinical-program-update-and-participate-in-a-panel-on-biomarkers-at-2026-lewy-body-dementia-association-annual-meeting</guid>
<pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
<description>Update will include new MRI analyses from the Phase 2b RewinD-LB clinical trial, status of global regulatory discussions, and finalized Phase 3 trial design</description>
</item>
<item>
<title>CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod’s Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer’s Disease Co-Pathology</title>
<link>https://6ix.com/company/cervomed-inc/news/cervomed-announces-new-data-at-the-adpdtm-2026-scientific-conference-that-reinforce-neflamapimods-positive-effects-in-dementia-with-lewy-bodies-dlb-in-patients-without-alzheimers-disease-co-pathology</link>
<guid isPermaLink="true">https://6ix.com/company/cervomed-inc/news/cervomed-announces-new-data-at-the-adpdtm-2026-scientific-conference-that-reinforce-neflamapimods-positive-effects-in-dementia-with-lewy-bodies-dlb-in-patients-without-alzheimers-disease-co-pathology</guid>
<pubDate>Thu, 19 Mar 2026 04:00:00 GMT</pubDate>
<description>New analyses show DLB patients with lower plasma pTau181 levels — indicating an earlier stage of disease and absence of Alzheimer’s disease (AD) co-pathology</description>
</item>
<item>
<title>CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates</title>
<link>https://6ix.com/company/cervomed-inc/news/cervomed-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-updates</link>
<guid isPermaLink="true">https://6ix.com/company/cervomed-inc/news/cervomed-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-updates</guid>
<pubDate>Tue, 17 Mar 2026 11:30:00 GMT</pubDate>
<description>Reported positive Phase 2b RewinD-LB clinical data at CTAD 2025; additional analyses to be presented at AD/PD 2026 Obtained alignment with FDA and global regulators for planned Phase 3 trial design in patients with DLB and selected Phase 3 formulation, dose and dosing regimen Multiple potential catalysts anticipated in the second half of 2026, including initiation of the planned Phase 3 trial, topline data from Phase 2a ischemic stroke recovery trial, initial topline data from Phase 2a primary p</description>
</item>
<item>
<title>CervoMed Announces Presentations at Upcoming AD/PD™ 2026 Scientific Conference</title>
<link>https://6ix.com/company/cervomed-inc/news/cervomed-announces-presentations-at-upcoming-adpdtm-2026-scientific-conference-6</link>
<guid isPermaLink="true">https://6ix.com/company/cervomed-inc/news/cervomed-announces-presentations-at-upcoming-adpdtm-2026-scientific-conference-6</guid>
<pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
<description>Data further support choice of patient population and dosing regimen in CervoMed's planned Phase 3 trial in dementia with Lewy bodies (DLB) DLB is the second</description>
</item>
<item>
<title>CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies</title>
<link>https://6ix.com/company/cervomed-inc/news/cervomed-announces-selection-of-formulation-and-dosing-regimen-for-planned-phase-3-trial-in-patients-with-dementia-with-lewy-bodies</link>
<guid isPermaLink="true">https://6ix.com/company/cervomed-inc/news/cervomed-announces-selection-of-formulation-and-dosing-regimen-for-planned-phase-3-trial-in-patients-with-dementia-with-lewy-bodies</guid>
<pubDate>Wed, 04 Mar 2026 12:30:00 GMT</pubDate>
<description>Bioavailability data recently obtained from Phase 1 study with a stable crystal form of neflamapimod manufactured using a new, controlled manufacturing process Pharmacokinetic profile of the new, stable crystal form of neflamapimod largely overlaps with the therapeutically active drug product used in Phase 2b trial extension To ensure that plasma drug concentrations associated with therapeutic activity are achieved, dosing regimen in the planned Phase 3 trial in dementia with Lewy bodies will be</description>
</item>
<item>
<title>CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform designed to prioritize promising treatments for Amyotrophic Lateral Sclerosis</title>
<link>https://6ix.com/company/cervomed-inc/news/cervomeds-neflamapimod-elected-for-inclusion-in-uk-experts-als-platform-designed-to-prioritize-promising-treatments-for-amyotrophic-lateral-sclerosis</link>
<guid isPermaLink="true">https://6ix.com/company/cervomed-inc/news/cervomeds-neflamapimod-elected-for-inclusion-in-uk-experts-als-platform-designed-to-prioritize-promising-treatments-for-amyotrophic-lateral-sclerosis</guid>
<pubDate>Wed, 18 Feb 2026 05:00:00 GMT</pubDate>
<description>Neflamapimod endorsement based on targeted mechanism of action, demonstrated clinical activity in neurodegenerative diseases, and encouraging translational</description>
</item>
<item>
<title>CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies</title>
<link>https://6ix.com/company/cervomed-inc/news/cervomed-announces-breaking-data-18th-220000049</link>
<guid isPermaLink="true">https://6ix.com/company/cervomed-inc/news/cervomed-announces-breaking-data-18th-220000049</guid>
<pubDate>Thu, 04 Dec 2025 22:00:00 GMT</pubDate>
<description>Phase 2b trial showed significant improvements on primary and key secondary outcomes measures, most prominently in patients without AD co-pathology Significant reduction in key neurodegeneration biomarker correlated with treatment response, suggesting neflamapimod may act on underlying disease CervoMed preparing to initiate Phase 3 registrational trial in patients with DLB in the second half of 2026 BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Today in a late-breaking oral session at the 18th Clini</description>
</item>
<item>
<title>CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)</title>
<link>https://6ix.com/company/cervomed-inc/news/cervomed-presents-plasma-biomarker-data-120000410</link>
<guid isPermaLink="true">https://6ix.com/company/cervomed-inc/news/cervomed-presents-plasma-biomarker-data-120000410</guid>
<pubDate>Tue, 02 Dec 2025 12:00:00 GMT</pubDate>
<description>1st of two presentations with results from Phase 2b study of neflamapimod at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference Data demonstrates neflamapimod treatment led to significant reductions in plasma glial fibrillary acidic protein (GFAP), a key marker of neuroinflammation-associated neurodegeneration, and increased beta amyloid (A) 42/40 ratio in DLB Correlation of the effects of neflamapimod on plasma GFAP with positive treatment response, as assessed by CDR-SB, support</description>
</item>
<item>
<title>CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference</title>
<link>https://6ix.com/company/cervomed-inc/news/cervomed-share-data-neflamapimod-treatment-120000235</link>
<guid isPermaLink="true">https://6ix.com/company/cervomed-inc/news/cervomed-share-data-neflamapimod-treatment-120000235</guid>
<pubDate>Mon, 24 Nov 2025 12:00:00 GMT</pubDate>
<description>Late-breaking oral presentation by a leading global authority in Dementia with Lewy bodies (DLB) to highlight updated data from Phase 2b study on neflamapimod treatment for DLB New data demonstrating the utility of neflamapimod and its effects on key neurodegeneration biomarkers in DLB will also be highlighted in poster session BOSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders, toda</description>
</item>
<item>
<title>CervoMed Reports Third Quarter 2025 Financial Results and Provides Corporate Updates</title>
<link>https://6ix.com/company/cervomed-inc/news/cervomed-reports-third-quarter-2025-120000207</link>
<guid isPermaLink="true">https://6ix.com/company/cervomed-inc/news/cervomed-reports-third-quarter-2025-120000207</guid>
<pubDate>Mon, 10 Nov 2025 12:00:00 GMT</pubDate>
<description>Aligned with U.S Food and Drug Administration (FDA) on design of planned Phase 3 clinical trial of neflamapimod in patients with dementia with Lewy bodies (DLB) Reported 32-week data from Phase 2b RewinD-LB trial showing neflamapimod treatment in patients with DLB had a durable beneficial effect on clinical progression and resulted in substantial reductions in plasma levels of a well-established biomarker of neurodegeneration Meeting with global regulators in coming months and preparing for glob</description>
</item>
<item>
<title>CervoMed Announces Alignment with FDA on Registration Path for Neflamapimod in Dementia with Lewy Bodies</title>
<link>https://6ix.com/company/cervomed-inc/news/cervomed-announces-alignment-fda-registration-120000815</link>
<guid isPermaLink="true">https://6ix.com/company/cervomed-inc/news/cervomed-announces-alignment-fda-registration-120000815</guid>
<pubDate>Tue, 04 Nov 2025 12:00:00 GMT</pubDate>
<description>FDA feedback enables CervoMed to proceed with proposed endpoints, patient enrichment strategy, and other key aspects of Phase 3 trial design to support potential New Drug Application CervoMed is advancing preparations for global pivotal trial initiation in the second half of 2026 BOSTON, Nov. 04, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO) (CervoMed or the Company), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced it has rece</description>
</item>
<item>
<title>CervoMed Strengthens Board with Appointment of Life Sciences Business Strategy Leader David Quigley</title>
<link>https://6ix.com/company/cervomed-inc/news/cervomed-strengthens-board-appointment-life-120000492</link>
<guid isPermaLink="true">https://6ix.com/company/cervomed-inc/news/cervomed-strengthens-board-appointment-life-120000492</guid>
<pubDate>Tue, 28 Oct 2025 12:00:00 GMT</pubDate>
<description>Mr. Quigley most recently led McKinsey & Company’s Private Capital practice and previously led various Life Sciences practices at the firm Appointment adds deep business strategy, transactional, and commercial expertise as CervoMed prepares for Phase 3 and commercialization planning BOSTON, Oct. 28, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO) (CervoMed or the Company), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced the appo</description>
</item>
<item>
<title>CervoMed to Present at the Emerging Growth Conference</title>
<link>https://6ix.com/company/cervomed-inc/news/cervomed-to-present-at-the-emerging-growth-conference</link>
<guid isPermaLink="true">https://6ix.com/company/cervomed-inc/news/cervomed-to-present-at-the-emerging-growth-conference</guid>
<pubDate>Mon, 20 Oct 2025 04:00:00 GMT</pubDate>
<description>BOSTON, Oct. 20, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic</description>
</item>
<item>
<title>CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies</title>
<link>https://6ix.com/company/cervomed-inc/news/cervomed-announces-data-phase-2b-110000037</link>
<guid isPermaLink="true">https://6ix.com/company/cervomed-inc/news/cervomed-announces-data-phase-2b-110000037</guid>
<pubDate>Wed, 08 Oct 2025 11:00:00 GMT</pubDate>
<description>Significant improvement relative to placebo on primary outcome measure, change in Clinical Dementia Rating Sum of Boxes (CDR-SB), demonstrated in a within-subject analysis in participants with low likelihood of having Alzheimer’s disease (AD) co-pathology Significant reduction in plasma levels of a well-established biomarker of neurodegeneration, plasma glial fibrillary acidic protein (GFAP), correlated to treatment response assessed by CDR-SB CervoMed anticipates U.S. Food and Drug Administrati</description>
</item>
<item>
<title>CervoMed Appoints Matthew Winton, Ph.D., as Chief Commercial and Business Officer</title>
<link>https://6ix.com/company/cervomed-inc/news/cervomed-appoints-matthew-winton-ph-120000039</link>
<guid isPermaLink="true">https://6ix.com/company/cervomed-inc/news/cervomed-appoints-matthew-winton-ph-120000039</guid>
<pubDate>Tue, 07 Oct 2025 12:00:00 GMT</pubDate>
<description>Expanding executive leadership team to prepare for late-stage development, strategic organizational growth, and market readinessBOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced the appointment of Matthew Winton, Ph.D., as Chief Commercial and Business Officer. Dr. Winton joins CervoMed with nearly two decades of experience in the global</description>
</item>
<item>
<title>CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference</title>
<link>https://6ix.com/company/cervomed-inc/news/cervomed-participate-4th-annual-roth-120000033</link>
<guid isPermaLink="true">https://6ix.com/company/cervomed-inc/news/cervomed-participate-4th-annual-roth-120000033</guid>
<pubDate>Thu, 02 Oct 2025 12:00:00 GMT</pubDate>
<description>BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Company management will participate in a panel discussion and one-on-one meetings at the upcoming 4th Annual ROTH Healthcare Opportunities Conference being held in New York, NY, on Thursday, October 9, 2025. Panel DetailsTitle: “Small Firms Tackling Blockbuster Indications”Date: Thurs</description>
</item>
<item>
<title>CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference</title>
<link>https://6ix.com/company/cervomed-inc/news/cervomed-highlights-neflamapimods-potential-benefits-113000224</link>
<guid isPermaLink="true">https://6ix.com/company/cervomed-inc/news/cervomed-highlights-neflamapimods-potential-benefits-113000224</guid>
<pubDate>Wed, 17 Sep 2025 11:30:00 GMT</pubDate>
<description>BOSTON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that the promising development program and potential benefits of neflamapimod for the treatment of Dementia with Lewy Bodies (DLB) were highlighted in a presentation on advances in DLB drug development by Dr. James Galvin at the 150th Annual American Neurological Association (ANA) confere</description>
</item>
<item>
<title>CervoMed to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/cervomed-inc/news/cervomed-participate-upcoming-investor-conferences-120000462</link>
<guid isPermaLink="true">https://6ix.com/company/cervomed-inc/news/cervomed-participate-upcoming-investor-conferences-120000462</guid>
<pubDate>Wed, 03 Sep 2025 12:00:00 GMT</pubDate>
<description>BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company management will participate in the following investor conferences during the month of September: H.C. Wainwright 27th Annual Global Investment ConferenceFormat: Presentation & 1x1 Investor MeetingsPresentation Date: Monday, September 8, 2025Presentation Time: 2:00 – 2:30 PM ETWebcast: https://journey.</description>
</item>
<item>
<title>CervoMed Reports Second Quarter 2025 Financial Results and Provides Corporate Updates</title>
<link>https://6ix.com/company/cervomed-inc/news/cervomed-reports-second-quarter-2025-120000244</link>
<guid isPermaLink="true">https://6ix.com/company/cervomed-inc/news/cervomed-reports-second-quarter-2025-120000244</guid>
<pubDate>Mon, 11 Aug 2025 12:00:00 GMT</pubDate>
<description>Reported 32-week data from Phase 2b RewinD-LB Trial Extension phase showing neflamapimod treatment resulted in a substantial reduction in clinically significant worsening compared to control arm over 32 weeks, which improved further among patients who have minimal evidence of Alzheimer’s disease (AD) co-pathology (ptau181 < 2.2 pg/mL at screening) At week 32 of the Extension phase, patients treated with neflamapimod demonstrated a significant reduction from baseline in plasma levels of glial fib</description>
</item>
</channel>
</rss>